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DObjective: The aim of this study was to evaluate the outcome of aortic valve replacement with the sutureless
Perceval S aortic valve bioprosthesis (Sorin Biomedica Cardio Srl, Saluggia, Italy).
Methods: This is a retrospective analysis of 314 patients (mean age, 77.9  5.0 years, mean European System for
Cardiac Operative Risk Evaluation II, 9.0%  7.6%) who underwent aortic valve replacement with the Perceval
S valvewith (94 patients) orwithout (220 patients) concomitant coronary artery bypass surgery at 5 European centers.
Results:ThePercevalS valvewas successfully implanted in all but 1 patient (99.7%). Themeanaortic crossclamp-
ing time was 43  20 minutes (isolated procedure, 39  15 minutes; concomitant coronary surgery, 52  26
minutes). Severe paravalvular leak occurred in 2 patients (0.6%). In-hospital mortality was 3.2% (1.4% after iso-
lated procedure and 7.4% after concomitant coronary surgery). In-hospital mortality was 2.8% and 4.0% among
patients with a European System for Cardiac Operative Risk Evaluation II less than 10% and 10% or greater,
respectively (P ¼ .558). Octogenarians had slightly higher in-hospital mortality (5.2% vs 2.0%, P ¼ .125; after
isolated procedure: 2.7% vs 0.7%, P ¼ .223; after concomitant coronary surgery: 9.5% vs 5.8%, P ¼ .491)
compared with younger patients. Full sternotomy did not increase the in-hospital mortality risk compared with
ministernotomy or minithoracotomy access (1.3% vs 1.4%, when adjusted for baseline covariates: P ¼ .921;
odds ratio, 0.886; 95% confidence interval, 0.064-12.346). One-year survival was 90.5%. Freedom from valve-
related mortality, stroke, endocarditis, and reoperation was 99.0%, 98.1%, 99.2%, and 98.3%, respectively.
Conclusions: The sutureless Perceval S valve is associated with excellent early survival in high-risk patients,
particularly among those undergoing an isolated procedure. Further studies are needed to prove the durability
of this bioprosthesis. (J Thorac Cardiovasc Surg 2014;148:865-71)Severe aortic valve stenosis is a common cardiac disease
among the elderly,1,2 and aortic valve replacement (AVR)
is still the treatment of choice.3 Among octogenarians,
AVR has been shown to provide late survival similar to
that in an age- and gender-matched general population.4
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The Journal of Thoracic and Casevere aortic valve stenosis5 will soon lead to a significant
increase in the need for AVR, particularly in very elderly
patients with multiple comorbidities. Transcatheter aortic
valve replacement (TAVR) has been embraced with
enthusiasm and has expanded the therapeutic possibilities
to patients ineligible for conventional AVR. Conversely,
the significantly increased costs, the inability to remove
the calcified aortic valve, and the resultant high incidence
of paravalvular leakage have been recognized as important
limitations of TAVR. Accordingly, a number of sutureless
aortic valve bioprostheses6 have been developed during
the last few years to facilitate surgical AVR and circumvent
prolonged aortic crossclamping and cardiopulmonary
bypass time and their related increased risk of mortality
and morbidity.7 Therefore, the aim of this study was to
assess the early and intermediate outcome after AVR with
the sutureless Perceval S aortic valve bioprosthesis (Sorin
Biomedica Cardio Srl, Saluggia, Italy) in a multicenter
European study.
METHODS
We performed a retrospective analysis of a consecutive series of patients
who underwent operation between September 2007 and September 2013 at
5 European institutions (Belgium, Finland, Germany, Italy, and Sweden).rdiovascular Surgery c Volume 148, Number 3 865
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
OR ¼ odds ratio
TAVR ¼ transcatheter aortic valve
replacement
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DThe baseline and operative characteristics of these patients are summarized
in Tables 1 and 2. The operative risk of these patients was estimated
according to the European System for Cardiac Operative Risk Evaluation
(euroSCORE) II.8
Permission to perform this study was granted by the ethical committees
of each participating center. The inclusion criterion for this study was any
isolated AVR with or without concomitant coronary artery bypass grafting
(CABG) using the Perceval S sutureless aortic valve prosthesis. Patients
undergoing any other concomitant cardiac procedure were excluded.
Data on patients’ characteristics and operative details were retrieved retro-
spectively from patients’ records. Follow-up data were retrieved by review-
ing hospital records or contacting the patient or her/his cardiologist or
general practitioner.
Indication for and Implantation Technique of
Perceval S Prosthesis
The Perceval S sutureless aortic valve prosthesis was mostly indicated
in patients with a perceived high operative risk. The implantation of this
valve was considered feasible when the aortic annulus size was between
19 and 27mm, and the ratio between the sinotubular diameter and the aortic
annulus was no more than 1.3. The ascending aorta was incised transver-
sally 1.5 cm above the sinotubular junction. The aortic valve was removed,
and the annulus was decalcified in the usual fashion in patients at each cen-
ter. Three 4/0 polypropylene guiding sutures were passed at the nadir of the
aortic annulus. An appropriately sized prosthesis was collapsed in a side
table and placed into the manufacturer’s holder. The 3 guiding sutures
were passed through the 3 green holes arising from the annular ring of
the prosthesis, which was consequently seated on the debrided annulus.
The aortic valve was opened, and the holder was removed. The field was
rinsed with warm saline, and the prosthesis was dilated at 4 atm for 30 sec-
onds. After closure of the aortotomy, transesophageal echocardiography
was performed to assess the correct implantation of the prosthesis and
the presence of any valve leak.
Outcome End Points
The main end points of this study were all-cause in-hospital and 1-year
mortality. Secondary outcome end points were implantation success, aortic
prosthesis valve-related mortality, stroke, reoperation on the aortic valve,
and prosthesis endocarditis. Implantation success was defined as an
implanted Perceval S that did not require replacement during the same
operation with another Perceval S or conventional valve prosthesis.
Statistical Analysis
Statistical analysis was performed using SPSS version 20 (IBM SPSS
Inc, Chicago, Ill). Fisher exact test, chi-square test, and Mann–Whitney
test were used for univariate analysis. No attempt to replace missing values
was made. Survival analysis was performed using the Kaplan–Meier and
Cox proportional hazards methods. The area under the receiver operating866 The Journal of Thoracic and Cardiovascular Surgcharacteristic curve was used to represent the discriminatory ability of
the euroSCORE II. The accuracy of the euroSCORE II was assessed by
the Brier score,9 which is the average squared difference between the pre-
dicted probability and the true occurrence of operative mortality. A Brier
score should be as close to 0 as possible, with 0.25 as an acceptable upper
cutoff.RESULTS
This analysis included 314 patients who underwent AVR
with the sutureless Perceval S aortic valve (Table 1). In
addition to the high prevalence of octogenarians (36.9%),
there was a rather high prevalence of female patients
(60.2%), patients with renal failure (creatinine clearance
<50 mL/min or dialysis, 23.5%), patients with peripheral
artery disease (23.9%), and patients with increased systolic
pulmonary pressure (>30 mm Hg, 44.4%). However, most
of these patients had a left ventricular ejection fraction
greater than 50% (86.3%), and surgery was performed on
elective basis in all but 2 patients (99.4%).
Concomitant CABG was performed in 94 patients
(29.9%). Minimally invasive access was used in 140 pa-
tients (44.6%) (Table 2). In the overall series, the mean
aortic crossclamping timewas 43 20 minutes, and cardio-
pulmonary bypass time was 73  28 minutes. These were
markedly shorter in patients undergoing isolated AVR
(Table 2). In particular, the aortic crossclamping time was
less than 30 minutes in 79 patients (25.2%), more specif-
ically in 64 patients (29.1%) who underwent isolated
AVR and in 15 patients (16.0%) who underwent concomi-
tant CABG.Early Outcome
The Perceval S valve was successfully implanted in all
but 1 patient (99.7%). Severe paravalvular leak was
detected intraoperatively in 2 patients (0.6%), mild para-
valvular leak was detected in 38 patients (12.1%), and no
paravalvular leak was detected in 274 patients (87.3%).
Redo conventional AVRwas required during the same in-
hospital stay in 3 patients: the 2 patients with the mentioned
severe paravalvular leakage and 1 patient with prosthesis
dislodgment.
In-hospital mortality in the overall series was 3.2%
(1.4% after isolated aortic valve procedure and 7.4% after
concomitant CABG, P ¼ .009). Six patients died of multi-
organ failure, 3 patients died of sepsis, and 1 patient died of
respiratory failure. Among these early deaths, only 2
patients had mild paravalvular leak and the remaining 8
patients did not have any paravalvular leak. None of them
required reoperation on the valve prosthesis, and no
valve-related early mortality occurred in this series. Other
early adverse events and length of stay in the intensive
care unit and in hospital are summarized in Table 3.
Themean euroSCORE II in the overall series was 9.0%
7.6% (median, 7.0%; range, 1.08-60.0). The area under theery c September 2014
TABLE 1. Baseline characteristics of patients who underwent aortic
valve replacement with the Perceval S sutureless aortic valve
bioprosthesis
Clinical variables No. (%)
Age (y) 77.9  5.0
Octogenarians 116 (36.9)
Female 189 (60.2)
Diabetes 94 (29.9)
Insulin-dependent diabetes 32 (10.2)
Creatinine clearance
>85 mL/min 114 (36.3)
50-85 mL/min 126 (40.1)
<50 mL/min 73 (23.2)
On dialysis 1 (0.3)
New York Heart Association class
I 1 (0.3)
II 60 (19.1)
III 243 (77.4)
IV 10 (3.2)
Poor mobility 41 (13.1)
Chronic lung disease 56 (17.8)
Extracardiac arteriopathy 75 (23.9)
Left ventricular ejection fraction
>50% 271 (86.3)
31%-50% 42 (13.4)
21%-30% 1 (0.3)
Systolic pulmonary artery pressure
30 mm Hg 143 (45.5)
31-55 mm Hg 136 (43.3)
>55 mm Hg 35 (11.1)
Indication for surgery
Stenosis 176 (56.1)
Regurgitation 1 (0.3)
Mixed pathology 137 (43.6)
Peak gradient (mm Hg) 84.6  23.6
Mean gradient (mm Hg) 51.9  18.3
AVA (cm2) 0.68  0.2
Active endocarditis 0 (0)
Critical preoperative state 1 (0.3)
Elective procedure 312 (99.4)
Previous cardiac surgery 24 (7.6)
Aortic valve surgery 9 (2.9)
Permanent pace-maker 9 (2.9)
euroSCORE II (%) 9.0  7.6
Continuous variables are reported as mean  standard deviation; dichotomous vari-
ables are reported as counts and percentages in parentheses. Definition criteria for
preoperative variables are according to euroSCORE II. AVA, Aortic valve area; euro-
SCORE, European System for Cardiac Operative Risk Evaluation.
TABLE 2. Operative data on patients who underwent aortic valve
replacement with the Perceval S sutureless aortic valve bioprosthesis
Operative data No. (%)
Access
Full sternotomy 174 (55.4)
Ministernotomy 131 (41.7)
Minithoracotomy 9 (2.9)
Concomitant CABG 94 (29.9)
No. of distal anastomoses 1.78  0.88
Prosthesis size
Small 37 (11.8)
Medium 135 (43.0)
Large 126 (40.1)
Extra large 16 (5.1)
Overall series
Aortic crossclamping time (min) 43  20
Aortic crossclamping time<30 min 79 (25.2)
Cardiopulmonary bypass time (min) 73  28
Cardiopulmonary bypass time<60 min 105 (33.4)
Isolated AVR
Aortic crossclamping time (min) 39  15
Aortic crossclamping time<30 min 64 (29.1)
Cardiopulmonary bypass time (min) 66  23
Cardiopulmonary bypass time<60 min 93 (42.3)
Combined procedure
Aortic crossclamping time (min) 52  26
Aortic crossclamping time<30 min 15 (16.0)
Cardiopulmonary bypass time (min) 88  32
Cardiopulmonary bypass time<60 min 12 (12.8)
Continuous variables are reported as mean  standard deviation; dichotomous vari-
ables are reported as counts and percentages in parentheses. AVR, Aortic valve
replacement; CABG, coronary artery bypass grafting.
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method was 0.65 (95% confidence interval [CI], 0.48-
0.81). The Brier score for the euroSCORE II in this series
was 0.038, indicating a good precision in prediction proba-
bility. However, the Brier score increased markedly with
increasing quartiles (<4, 4-7, 7-11, and>11) of the euro-
SCORE II (0.014, 0.023, 0.043, and 0.073, respectively).
In this series, we observed a marked increase in the
operative mortality in the upper quartile of the euroSCOREThe Journal of Thoracic and CaII (Figure 1); thus, the euroSCORE II was dichotomized
according to a cutoff value of 10%. In the overall series,
in-hospital mortality was 2.8% in patients with a
euroSCORE II less than 10% and 4.0% in those with a
euroSCORE II 10% or greater (P ¼ .558): 2.0% and 0%
(P ¼ .243), respectively, in those who underwent isolated
AVR, and 4.8% and 12.9% (P ¼ .158), respectively, in
those who underwent concomitant CABG.
Aortic crossclamping time was a determinant of in-
hospital mortality in the overall series (area under the curve,
0.712; 95% CI, 0.550-0.874; adjusted for euroSCORE II,
P ¼ .005; odds ratio [OR], 1.033; 95% CI, 1.010-1.056)
and in patients who underwent concomitant CABG (area
under the curve, 0.758; 95% CI, 0.581-0.934; adjusted for
euroSCORE II, P ¼ .027; OR, 1.031; 95% CI,
1.004-1.059), but not among those who underwent an
isolated procedure (area under the curve, 0.459; 95% CI,
0.323-0.596; adjusted for euroSCORE II, P ¼ .658; OR,
1.033; 95% CI, 0.901-1.068).
Octogenarians had a higher in-hospital mortality than
younger patients (5.2% vs 2.0%, P ¼ .125), but this was
not statistically significant. Similar findings were observed
in patients who underwent isolated AVR (2.7% vs 0.7%,rdiovascular Surgery c Volume 148, Number 3 867
TABLE 3. Postoperative data on patients who underwent aortic valve
replacement with the Perceval S sutureless aortic valve bioprosthesis
Postoperative outcomes No. (%)
Implantation success 313 (99.7)
Intraoperative paravalvular leak
None 274 (87.3)
Mild 38 (12.1)
Severe 2 (0.6)
Prosthesis dislodgment 1 (0.3)
Conversion to conventional AVR 2 (0.6)
Stroke 6 (1.9)
De novo dialysis 5 (1.6)
Pacemaker implantation 25 (8.0)
Reoperation for bleeding 8 (2.5)
Intensive care unit stay (d) 3.2  3.4
In-hospital stay (d) 13.4  6.5
In-hospital/30-d mortality 10 (3.2)
After isolated procedure 3 (1.4)
After combined procedure 7 (7.4)
Prosthesis-related early mortality 0 (0)
Continuous variables are reported as mean  standard deviation; dichotomous vari-
ables are reported as counts and percentages in parentheses. AVR, Aortic valve
replacement.
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DP ¼ .223) and patients who underwent concomitant CABG
(9.5% vs 5.8%, P ¼ .491).
Echocardiographic data were available in 305 patients.
The mean peak transvalvular gradient was 27  11 mm
Hg, and the mean gradient was 14  6 mm Hg.Full Sternotomy Versus Ministernotomy/
Minithoracotomy
Patients undergoing full sternotomy had a lower euro-
SCORE II than those undergoing ministernotomy/FIGURE 1. Observed in-hospital mortality rates according to euroSCORE II q
Biomedica Cardio Srl, Saluggia, Italy). The predicted mortality rates are acco
mortality ratio in each euroSCORE II quartile is shown. euroSCORE, Europea
868 The Journal of Thoracic and Cardiovascular Surgminithoracotomy (mean, 8.2%  10.2% vs 9.1%  6.3%,
P<.0001). Full sternotomywas associatedwith significantly
shorter aortic crossclamping time (35.6  16.3 minutes vs
41.1 14.3 minutes, P¼ .003) and cardiopulmonary bypass
duration (58.2  21.7 minutes vs 71.0  22.2 minutes,
P<.0001) compared with ministernotomy or minithoracot-
omy access. Full sternotomy was associated with a similar
mortality risk compared with ministernotomy or minithora-
cotomy access (1.3% vs 1.4%, when adjusted for age, creat-
inine clearance, left ventricular ejection fraction, pulmonary
disease, systolic pulmonary pressure, and prior cardiac sur-
gery: P ¼ .921; OR, 0.886; 95% CI, 0.064-12.346,
when adjusted for euroSCORE II: P ¼ .844; OR, 1.284;
95% CI, 0.107-15.376).Intermediate Outcome
The overall follow-up included 366.3 patient/years with a
median follow-up interval of 0.9 years (mean, 1.1 1.0; in-
terquartile range, 0.08-3.02 years). One-year and 2-year
survivals were 90.5% and 87%, respectively (Figure 2).
At the same intervals and including the operative events,
freedom from valve-related mortality was 99.0% and
98.0%, freedom from stroke was 98.1% and 98.1%,
freedom from endocarditis was 99.2% and 99.2%, and
freedom from reoperation was 98.3% and 98.3%, respec-
tively. Peripheral thromboembolism was not observed in
any of these patients.DISCUSSION
The results of this multicenter study suggest that the use
of the sutureless Perceval S aortic valve bioprosthesis is
associated with excellent early results. These findings areuartiles after AVR with the sutureless Perceval S valve bioprosthesis (Sorin
rding to the mean euroSCORE II in each quartile. The observed/expected
n System for Cardiac Operative Risk Evaluation; O/E, observed expected.
ery c September 2014
FIGURE 2. Kaplan–Meier estimate of intermediate survival after AVR with the sutureless Perceval S aortic valve bioprosthesis.
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operative risk as indicated by the increased age and high
euroSCORE II. Indeed, 37% of the patients were octoge-
narians and 30% of the patients underwent concomitant
CABG, both factors having a marked impact on the risk
of postoperative adverse events. We did not compare the
results with a cohort of patients undergoing AVR with con-
ventional bioprosthesis or TAVR. Therefore, the evaluation
of the efficacy and safety of this sutureless bioprosthesis
relied on the comparison between the observed in-hospital
mortality and the mortality estimated by euroSCORE II.
The Brier score suggested that this risk scoring method is
a good predictor of mortality in these patients, even if its
value and the observed-expected mortality ratio increased
in the patients with the highest quartiles of euroSCORE II
(Figure 1). The euroSCORE II has been shown to have a
good observed–predicted ratio in patients undergoing con-
ventional AVR10-12 and TAVR.13-16 In the present study,
however, the euroSCORE II significantly overpredicted
the mortality risk of these elderly patients with numerous
comorbidities and undergoing AVR with the Perceval S
sutureless valve bioprosthesis. We speculate that this
discrepancy between observed and predicted mortality is
due to the significant reduction of the myocardial
ischemia time and duration of cardiopulmonary bypass,
and possibly to the benefits of removal of the aortic valve
with low rates of paravalvular leakage. Indeed, previous
TAVR series reported on patients with a mean
euroSCORE II similar to that in the present series, but
with results significantly poorer despite a similar
euroSCORE II predicted mortality.13-16 The beneficial
effects of sutureless valve implantation were particularly
evident in patients in the 3 highest quartiles of the
euroSCORE II (ie,>4%) (Figure 1) and patients undergo-
ing isolated AVR (mean euroSCORE II, 8.7%  7.9%).
When comparing our results with the data on conventionalThe Journal of Thoracic and CaAVR from a pooled analysis of 176 recent studies reporting
on approximately 700,000 patients,17 the operative mortal-
ity after conventional AVR with or without CABG was
4.3% (3.3% after isolated AVR and 5.5% after concomi-
tant CABG), which is markedly higher than that observed
in the present series. In that study, meta-regression indi-
cated that patients approaching 80 years of age have a mor-
tality risk of approximately 4% to 5% after isolated
conventional AVR and approximately 6% after concomi-
tant CABG.17 These figures increase to 7% and 10%,
respectively, among octogenarians.18,19 The relatively
high rate of implantation of permanent pacemakers
observed in our study is worth noting. At this stage, it is
not clear whether this could be related to the risk profile
of these patients or the need for dilatation of this
sutureless prosthesis, which may damage the conduction
system.
This study showed that patients requiring concomitant
CABG might benefit less from AVR with this sutureless
valve bioprosthesis compared with patients requiring iso-
lated AVR. It is well established that concomitant CABG
can be associated with a somewhat higher risk of adverse
events and poorer late outcome.17 To some extent, this
can be explained by the presence of coronary artery disease
and the need for longer aortic crossclamping time. The large
difference in operative mortality (1.4% after isolated AVR
and 7.4% after concomitant CABG, P ¼ .009), in the
absence of a marked increase in operative risk (euroSCORE
II: 8.8% vs 9.5%, P ¼ .047), suggests that alternative
less-invasive approaches, such as TAVR and percutaneous
coronary intervention, should be considered. A recent
meta-analysis showed that a series reporting on TAVR
with or without concomitant PCI reported a pooled rate of
6.3% operative mortality.20
Adjusted analysis showed that a minimally invasive
approach was associated with similar operative mortalityrdiovascular Surgery c Volume 148, Number 3 869
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cannot be considered conclusive because this series was
not powered to allow such a comparison. However, as indi-
cated in previous series,21 a minimally invasive approach
may not allow a crossclamping time as short as 30 minutes,
and this may jeopardize the benefits related to the implanta-
tion of this sutureless bioprosthesis. In the present series, a
full sternotomy allowed us to perform an isolated procedure
with a significantly shorter aortic crossclamping time
(35.6  16.3 minutes vs 41.1  14.3 minutes, P ¼ .003)
and cardiopulmonary bypass time (58.2  21.7 minutes
vs 71.0  22.2 minutes, P< .0001). However, some of
the reported benefits with minimal access surgery22
may become more evident with increasing experience,
which in turn may be confirmed as a valid alternative to
TAVR.23
Survival data from this series showed that this sutureless
bioprosthesis may be as durable as the conventional stented
bioprosthesis or TAVRprostheses in the short run (Figure 2).
Therefore, the benefits of implanting a Perceval S prosthesis
may not be limited to the early postoperative period, but we
speculate may be durable over time. However, this series is
characterized by a short follow-up, which is mostly due to
the recent experience with the prosthesis in some of the
centers involved in this multicenter study. The lack of data
on the durability of the Perceval S prosthesis prevents its
use in patients with a long life expectancy.
Study Limitations
The retrospective nature is the major limitation of this
study. This series included patients mostly treated on an
elective basis and with preserved left ventricular function.
Therefore, the results may not necessarily apply to
patients with impaired left ventricular function or requiring
urgent/emergency operation, that is, patients with the highest
operative risk. The lack of a control group, such as patients
undergoing AVR with conventional prostheses or TAVR,
prevents more conclusive results on the benefits associated
with the use of this sutureless valve. However, the experience
with this prosthesis is rather limited, and this study was
mainly focused on the evaluation of the feasibility and safety
of thismethod in severalEuropean centers. Further studies are
needed to clarify the clinical outcomes and the incidence of
paravalvular leakage during follow-up.
CONCLUSIONS
This multicenter retrospective study showed that the use
of the sutureless Perceval S aortic valve bioprosthesis is
associated with excellent early postoperative outcomes.
The benefits of a short period of myocardial ischemia
seem more pronounced in patients undergoing isolated
AVR and patients with a high euroSCORE II. A longer
follow-up is needed to define the structural and clinical
durability of this bioprosthesis. Further data are needed870 The Journal of Thoracic and Cardiovascular Surgon the potential benefits of this approach in patients
requiring coronary revascularization or any other cardiac
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DDiscussion
Dr Vinod H. Thourani (Atlanta, Ga). My disclosure is that I am
a researcher in the pivotal trial for the Perceval (Sorin Biomedica
Cardio Srl, Saluggia, Italy) system here in the United States.
I thank the Association for the privilege to discuss this
important and timely presentation, and I congratulate you for an
excellent presentation and your multinational study group for their
contribution.
Without rehashing the entire conclusions, the authors report on
94 patients undergoing AVR +CABG and 220 patients undergoing
isolated AVR. On the basis of a euroSCORE II of 9, I would
consider this to be more of a medium-risk population than a
high-risk population. I have 3 questions for you.
You didn’t talk about this much as far as resource use, but the
proposed advantage in some ways to the sutureless valve platform
is decreased aortic crossclamp time, which you have shown, and
this should transpose to some decreased intensive care unit
(ICU) and length of stay. Did you see that in your sutureless valves,
did you see a decreased length of stay, and what was your length of
stay for the ICU and overall length of stay?
Dr Antonino S. Rubino.We believe that reducing crossclamp-
ing and cardiopulmonary bypass time may positively influence the
immediate postoperative outcomes. However, one of the major
limits of our study is that it is multicentric, and we have no
uniform policy in the different centers about when to discharge,
for example, patients from the ICU. So it could be difficult to
generalize on this topic.
Dr Thourani. In your article, you show that the overall length
of stay was 13 days and ICU stay was 3 days. So I think we need to
be cautious when transposing sutureless valve technology to over-
all decreased resource use.
The second question is with your results, and looking
specifically at the AVR + CABG population, especially in those
patients with a euroSCORE greater than 10, have you stopped
using the Perceval valve in those patients in whom you are showing
a relatively higher mortality in all respects?
Dr Rubino. No, we don’t stop performing this procedure. We
all know that the need for associated CABG increases the operative
risk in this cohort of patients, and that the use of a sutureless
prosthesis might improve postoperative outcomes. We have also
shown in this presentation that the use of this prosthesis might
be more beneficial in those patients with a high-risk profile. So
we still keep on performing associated CABG.
Dr Thourani. The last question is more of a philosophical
question. I know that you also do transcatheter aortic valves. After
seeing these data, which patients would receive a stented valve,The Journal of Thoracic and Caa sutureless valve, or a transcatheter valve, because now we have
3 different options for our patients?
Dr Rubino. This allows me to give you a wider opportunity to
answer you. Again, I cannot answer about the policies in the other
centers elsewhere but only about the policy in our center in
Catania. We also do transcatheter valves, and we started with the
transaortic and transapical approach.
We discuss the cases of high-risk patients with our cardiolo-
gists. We do not believe that the cutoff should be pointed out
only by the euroSCORE, because there are some patients referred
to TAVI from local cardiologists who come back to our surgical
cohort, and there are some patients from the surgical cohort who
we send for TAVI. For an indication, we don’t have to rely only
on the age, for example, or the euroSCORE but also on other
severe comorbidities, such as severe neurologic dysfunction,
malignancies, or poor expected life. In these last situations, we
send them to the TAVI cohort.
We are happy to have these sutureless options, because this
allows us to widen the therapeutic options for our population. In
normal-risk patients, a standard conventional procedure should
be the optimal solution. The sutureless valve allows us to increase
the volume of a minimally invasive approach, which is also one of
the most frequent reasons that the cardiologists have when they
propose a TAVI, which is actually minimally invasive, to a patient.
So this prosthesis allows us to improve the minimally invasive
program in the center, and those patients who are at high surgical
risk independently from the mere euroSCORE are sent to TAVI.
Dr Thourani. Congratulations. This is a great article.
Dr Harold L. Lazar (Boston, Mass). I know you don’t have any
controls, but would you estimate how much crossclamp time, based
on your own series of isolated AVRs, you save with this technique?
Dr Rubino. In the standard conventional procedure, it is
40 minutes. If you put in stitches, you will need approximately
35 or 40 minutes of crossclamping. We tried and are implanting
some prostheses with running sutures that also allow us to reduce
the crossclamping time significantly. With this sutureless
prosthesis, our mean crossclamping time is approximately 23
minutes in our center. So there is a significant reduction. But one
of the key messages is that realistically with this prosthesis we
can move toward a minimally invasive approach.
Dr Lazar. Briefly, what technical tricks have you learned as far
as putting these valves in, especially with debriding the annulus?
Dr Rubino. This valve is particularly useful in those cases
when you do not want to manipulate the aorta. We have 2 cases
of almost porcelain aorta. We just dids a transverse aortotomy
approximately 1.5 cm above the sinotubular junction, more or
less at the level of the fat pad. We removed the valve, and we
put the valve in straight without touching the calcium.
To achieve a perfect and complete adhesion of the valve to the
annulus and to the root, apart from the respect of the geometric
relationship I showed before, it is more important to create an
almost perfect circular geometry. In our center we try to decalcify
the annulus almost completely, but what is really important with
this valve is to create a circular geometry. In the past before the
XL was available, we had cases of rescue surgery after TAVI,
and the annulus was large. So we performed a partial
decalcification, but we recreated a circular anatomy and put an L
inside, and the patient went home without any paravalvular leak.rdiovascular Surgery c Volume 148, Number 3 871
